Delivery of Powdered Vaccines for Improving Newborn Vaccination
提供粉状疫苗以改善新生儿疫苗接种
基本信息
- 批准号:10092941
- 负责人:
- 金额:$ 24.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdjuvanticityAdverse eventAge-MonthsAgonistAgreementAntibodiesAntibody titer measurementAntigen-Presenting CellsAntigensAnxietyAreaBackBacteriaBirthBlindnessCellsCellular PhoneCessation of lifeCodeCyclic GMPDepositionDermisDevelopmentDiffuseDiseaseDoseEncapsulatedEngineeringEpidermisFreeze DryingFrightFutureGenesHaemophilus influenzae type bHomeHumanHyaluronic AcidHydration statusImmune responseImmune systemImmunityImmunizationIn VitroIndividualInfantInfectionInterferonsIntramuscularLipid AMF59Maternal antibodyMediatingMeningitisModificationMusNeedlesNewborn InfantParentsPenetrationPolysaccharidesPowder dose formProductionSeriesSkinSurvivorsTechnologyTestingTimeTissuesVaccinationVaccine AntigenVaccinesadaptive immune responsealuminum sulfatebasebiomaterial compatibilitybooster vaccinedosageefficacy validationhealingimprovedin vivoinfluenza virus vaccineinorganic phosphatemicroporeminimally invasiveneonatal infectionneonatal micenervous system disordernew technologyporcine modelreconstitutionsealskin irritationskin vaccinationuptakevaccination schedulevaccination strategyvaccine delivery
项目摘要
Abstract
Objective of this proposal is to engineer a Powder-Laden, Dissolvable MicroNeedle Array
(PLD-MNA) to improve newborn Hib vaccination. Due to the immature immune system, most of
the newborn vaccines induce suboptimal immune responses and require multiple boosters to
induce a protective immunity. The lengthened vaccination schedule, in conjunction with a rapid
decline of maternal antibodies after birth, leaves a few months of a vulnerability period to
various infections for every newborn, which is the single major factor for a high rate of vaccine-
preventable diseases occurring in newborns. To eliminate or greatly shorten the vulnerable
period, we identified a potent adjuvant cGAMP, an agonist of the stimulator of IFN genes
(STING) that could robustly bolster adaptive immune responses in neonatal mice. We will
combine this potent adjuvant and powder-based epidermic vaccination to vigorously augment
Hib vaccine and reduce Hib vaccine dosage from the current 4 to 2 doses in this proposal. We
will first fabricate PLD-MNA encapsulated with Hib conjugated PRP-T vaccine and cGAMP and
characterize its loading capacity and delivery efficiency in both newborn mice and piglets. We
will also minimize skin irritation, if there is any, in a piglet model and optimize the dosage of
immunization in newborn mice. Aim 2 will validate whether prime at birth and boost 10 days later
with PLD-MNA packaged with PRP-T/cGAMP can induce a comparable or superior immune
response than four alum/intramuscular immunizations of PRP-T vaccine in the presence of
maternal antibodies. This needle-free, potentially home-use vaccination, if successful, would
represent a paradigm-shifting technology to augment many vaccines for newborns and infants,
because most of current infant vaccines are made in a form of powder and can be directly
loaded into the PLD-MNAs and applied to newborns.
摘要
本提案的目的是设计一种粉末状、可溶解的微针阵列
(PLD-MNA),以改善新生儿Hib疫苗接种。由于免疫系统不成熟,大多数
新生儿疫苗诱导次优免疫应答,
诱导保护性免疫。延长疫苗接种时间表,同时快速接种疫苗,
出生后母体抗体下降,留下几个月的脆弱期,
每个新生儿都有各种感染,这是疫苗接种率高的唯一主要因素,
可预防的新生儿疾病。消除或大大缩短脆弱的
期间,我们确定了一种有效的佐剂cGAMP,一种IFN基因刺激物的激动剂
(STING),其可以有力地支持新生小鼠的适应性免疫应答。我们将
联合收割机结合这种有效的佐剂和基于粉末的表皮疫苗接种,
Hib疫苗,并将Hib疫苗剂量从目前的4剂减少到2剂。我们
将首先制造用Hib缀合的PRP-T疫苗和cGAMP包封的PLD-MNA,
表征其在新生小鼠和仔猪中的负载能力和递送效率。我们
还将最小化小猪模型中的皮肤刺激(如果有的话),并优化
新生小鼠的免疫。Aim 2将验证是否在出生时预充并在10天后加强
与包装有PRP-T/cGAMP的PLD-MNA相比,
反应比PRP-T疫苗的四次明矾/肌内免疫在存在
母体抗体。这种无针的,可能家庭使用的疫苗接种,如果成功,
代表了一种范式转变技术,可以为新生儿和婴儿增加许多疫苗,
由于目前大多数婴儿疫苗是以粉末形式制成的,
装载到PLD-MNAs中并应用于新生儿。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mei X Wu其他文献
Mei X Wu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mei X Wu', 18)}}的其他基金
A new mucosal adjuvant for augmenting influenza vaccines in elderly
一种用于增强老年人流感疫苗接种效果的新型粘膜佐剂
- 批准号:
10409833 - 财政年份:2021
- 资助金额:
$ 24.73万 - 项目类别:
A new mucosal adjuvant for augmenting influenza vaccines in elderly
一种用于增强老年人流感疫苗接种效果的新型粘膜佐剂
- 批准号:
10304406 - 财政年份:2021
- 资助金额:
$ 24.73万 - 项目类别:
Biomimetic nanoparticles to enhance the breadth of influenza vaccines
仿生纳米颗粒可增强流感疫苗的广度
- 批准号:
10455053 - 财政年份:2020
- 资助金额:
$ 24.73万 - 项目类别:
Sample-free onsite detection of cocaine using microneedles via laser-treated skin
使用微针通过激光处理的皮肤对可卡因进行无样品现场检测
- 批准号:
9044652 - 财政年份:2016
- 资助金额:
$ 24.73万 - 项目类别:
Laser-facilitated powder-allergen delivery for epicutaneous immunotherapy
用于表皮免疫治疗的激光促进粉末过敏原递送
- 批准号:
8892996 - 财政年份:2014
- 资助金额:
$ 24.73万 - 项目类别:
Laser-facilitated powder-allergen delivery for epicutaneous immunotherapy
用于表皮免疫治疗的激光促进粉末过敏原递送
- 批准号:
8770696 - 财政年份:2014
- 资助金额:
$ 24.73万 - 项目类别:
Laser-facilitated delivery of malarial sporozoites from the skin to liver
激光促进疟疾子孢子从皮肤输送至肝脏
- 批准号:
8495256 - 财政年份:2012
- 资助金额:
$ 24.73万 - 项目类别:
Laser-facilitated delivery of malarial sporozoites from the skin to liver
激光促进疟疾子孢子从皮肤输送至肝脏
- 批准号:
8385605 - 财政年份:2012
- 资助金额:
$ 24.73万 - 项目类别:
Boosting Flu Vaccination without Adjuvant Injection
无需注射佐剂即可加强流感疫苗接种
- 批准号:
8263742 - 财政年份:2011
- 资助金额:
$ 24.73万 - 项目类别:
IEX-1 as a potential biomarker for early detection of myelodysplastic syndromes
IEX-1 作为早期检测骨髓增生异常综合征的潜在生物标志物
- 批准号:
8311631 - 财政年份:2011
- 资助金额:
$ 24.73万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 24.73万 - 项目类别: